

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/078968 A1

(51) International Patent Classification:
A61P 35/02 (2006.01) **C07K 16/28** (2006.01)

(21) International Application Number:
PCT/EP2022/080619

(22) International Filing Date:
03 November 2022 (03.11.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21206329.1 03 November 2021 (03.11.2021) EP
21213774.9 10 December 2021 (10.12.2021) EP
22187301.1 27 July 2022 (27.07.2022) EP

(71) Applicant: **AFFIMED GMBH** [DE/DE]; Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg (DE).

(72) Inventors: **KOCH, Joachim**; c/o Affimed GmbH, Im Neuenheimer Feld 582, 69120 Heidelberg (DE). **PAHL, Jens**; c/o Affimed GmbH, Im Neuenheimer Feld 582, 69120 Heidelberg (DE). **ROSS, Thorsten**; c/o Affimed GmbH, Im Neuenheimer Feld 582, 69120 Heidelberg (DE). **SIEGLER, Jana-Julia**; c/o Affimed GmbH, Im Neuenheimer Feld 582, 69120 Heidelberg (DE). **DULAT, Holger**; c/o Affimed GmbH, Im Neuenheimer Feld 582, 69120 Heidelberg (DE).

(74) Agent: **KOCH, Andreas** et al.; c/o Schiweck Weinzierl Koch, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: BISPECIFIC CD16A BINDERS

(57) Abstract: The present invention relates to a bispecific antibody construct comprising (a) a first binding domain (A), which is capable of specifically binding to a first target (A') that is CD16A on the surface of an immune effector cell, wherein the first binding domain comprises: (i) a VL region comprising CDR-L1 as depicted in SEQ ID NO: 4, a CDR-L2 as depicted in SEQ ID NO: 5, and a CDR-L3 as depicted in SEQ ID NO: 6; and (ii) a VH region as depicted in SEQ ID NO: 7 or SEQ ID NO: 134; and (b) a second binding domain (B), which is capable of specifically binding to a second target (B') that is an antigen on the surface of a target cell. The present invention also relates to related nucleic acid molecules, vectors, host cells, methods of producing the antibody constructs, pharmaceutical compositions, medical uses, and kits.



WO 2023/078968 A1